Formulary Search Results for: oxycodone
4.7.2 Opioid analgesics - View Category
Restrictions:
Use is restricted to patients in whom morphine is ineffective or not tolerated. The combination product of oxycodone and naloxone (Targinact®) is not recommended for use in NHS Scotland by the SMC and is non-Formulary.
Prescribing Notes:
- Tablets and capsules should be prescribed by brand name and the current brands of choice for modified-release and immediate release preparations respectively are Oxypro® and Shortec®.
- Oral liquid is no longer available as the Shortec® brand. Please prescribe generically to allow timely supply of other available brands.
4.7.2 Opioid analgesics - View Category
Restrictions:
The injection is restricted to initiation by specialists in palliative care and oncology for use in patients for whom morphine/diamorphine is ineffective or not tolerated. Oxycodone injection is non-Formulary for post-operative use.
Oxycodone 10mg/ml injection is restricted to use in the treatment of moderate to severe pain in cancer in those patients who have difficulty in tolerating morphine or diamorphine therapy.
The 50mg/ml injection is further restricted to those patients who require either a high dose bolus injection (>2ml of the 10mg/1ml injection) of oxycodone, or oxycodone delivered via a continuous subcutaneous infusion where the use of the 10mg/ml injection would result in a total volume of all medicines which necessitates the use of an additional syringe pump.